PMID- 25027585
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20220311
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 13
DP  - 2014 Jul 16
TI  - Effects of pitavastatin versus atorvastatin on the peripheral endothelial 
      progenitor cells and vascular endothelial growth factor in high-risk patients: a 
      pilot prospective, double-blind, randomized study.
PG  - 111
LID - 10.1186/s12933-014-0111-1 [doi]
AB  - BACKGROUND: Circulating endothelial progenitor cells (EPCs) reflect endothelial 
      repair capacity and may be a significant marker for the clinical outcomes of 
      cardiovascular disease. While some high-dose statin treatments may improve 
      endothelial function, it is not known whether different statins may have similar 
      effects on EPCs.This study aimed to investigate the potential class effects of 
      different statin treatment including pitavastatin and atorvastatin on circulating 
      EPCs in clinical setting. METHODS: A pilot prospective, double-blind, randomized 
      study was conducted to evaluate the ordinary dose of pitavastatin (2 mg daily) or 
      atorvastatin (10 mg daily) treatment for 12 weeks on circulating EPCs in patients 
      with cardiovascular risk such as hypercholesterolemia and type 2 diabetes 
      mellitus (T2DM). Additional in vitro study was conducted to clarify the direct 
      effects of both statins on EPCs from the patients. RESULTS: A total of 26 
      patients (19 with T2DM) completed the study. While the lipid-lowering effects 
      were similar in both treatments, the counts of circulating CD34+KDR+EPCs were 
      significantly increased (from 0.021 +/- 0.015 to 0.054 +/- 0.044% of gated 
      mononuclear cells, P < 0.05) only by pitavastatin treatment. Besides, plasma 
      asymmetric dimethylarginine level was reduced (from 0.68 +/- 0.10 to 
      0.53 +/- 0.12 mumol/L, P < 0.05) by atorvastatin, and plasma vascular endothelial 
      growth factor (VEGF) level was increased (from 74.33 +/- 32.26 to 
      98.65 +/- 46.64 pg/mL, P < 0.05) by pitavastatin. In the in vitro study, while both 
      statins increased endothelial nitric oxide synthase (eNOS) expression, only 
      pitavastatin increased the phosphorylation of eNOS in EPCs. Pitavastatin but not 
      atorvastatin ameliorated the adhesion ability of early EPCs and the migration and 
      tube formation capacities of late EPCs. CONCLUSIONS: While both statins similarly 
      reduced plasma lipids, only pitavastatin increased plasma VEGF level and 
      circulating EPCs in high-risk patients, which is probably related to the 
      differential pleiotropic effects of different statins. TRIAL REGISTRATION: This 
      trial is registered at ClinicalTrials.gov, NCT01386853.
FAU - Lin, Liang-Yu
AU  - Lin LY
FAU - Huang, Chin-Chou
AU  - Huang CC
FAU - Chen, Jia-Shiong
AU  - Chen JS
FAU - Wu, Tao-Cheng
AU  - Wu TC
FAU - Leu, Hsin-Bang
AU  - Leu HB
FAU - Huang, Po-Hsun
AU  - Huang PH
FAU - Chang, Ting-Ting
AU  - Chang TT
FAU - Lin, Shing-Jong
AU  - Lin SJ
FAU - Chen, Jaw-Wen
AU  - Chen JW
LA  - eng
SI  - ClinicalTrials.gov/NCT01386853
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140716
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Biomarkers)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Pyrroles)
RN  - 0 (Quinolines)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - A0JWA85V8F (Atorvastatin)
RN  - M5681Q5F9P (pitavastatin)
SB  - IM
MH  - Aged
MH  - Atorvastatin
MH  - Biomarkers/blood
MH  - Diabetes Mellitus, Type 2/blood/drug therapy
MH  - Double-Blind Method
MH  - Endothelial Progenitor Cells/drug effects/*metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Heptanoic Acids/pharmacology/*therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology/*therapeutic use
MH  - Hypercholesterolemia/blood/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Pyrroles/pharmacology/*therapeutic use
MH  - Quinolines/pharmacology/*therapeutic use
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/*blood
PMC - PMC4223413
EDAT- 2014/07/17 06:00
MHDA- 2015/03/31 06:00
PMCR- 2014/07/16
CRDT- 2014/07/17 06:00
PHST- 2014/04/26 00:00 [received]
PHST- 2014/07/07 00:00 [accepted]
PHST- 2014/07/17 06:00 [entrez]
PHST- 2014/07/17 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
PHST- 2014/07/16 00:00 [pmc-release]
AID - s12933-014-0111-1 [pii]
AID - 10.1186/s12933-014-0111-1 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2014 Jul 16;13:111. doi: 10.1186/s12933-014-0111-1.